top of page
News
We're thrilled to share the latest developments from our company.

Suche
ODI Pharma
12. Nov. 20243 Min. Lesezeit
ODI Pharma appoints new CEO
The board of ODI Pharma AB (“ODI” or the “Company”) has today appointed Jan-Mark Edewaard as the new CEO of ODI as of January 1, 2025....
0 Kommentare
ODI Pharma
30. Okt. 20242 Min. Lesezeit
Proposal for change in the Board of Directors of ODI Pharma AB
Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting...
0 Kommentare
ODI Pharma
30. Okt. 20248 Min. Lesezeit
ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA,...
0 Kommentare
ODI Pharma
2. Mai 20242 Min. Lesezeit
Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024
ODI Pharma AB (“ODI” or the “Company”) announces today that the preliminary financial results for the third quarter of fiscal year...
0 Kommentare
ODI Pharma
6. Dez. 20233 Min. Lesezeit
ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek
ODI Pharma AB (“ODI” or the “Company”) announces today the sale of the skincare brand kandol. to Niclas Kappelin. The transaction, valued...
0 Kommentare
ODI Pharma
7. Aug. 20233 Min. Lesezeit
ODI Pharma AB enters into exclusive collaboration with Synoptis Pharma Sp. z o.o.
ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has entered through its Polish subsidiary into a collaboration...
0 Kommentare
ODI Pharma
1. Juni 20232 Min. Lesezeit
ODI Pharma AB receives loan financing of EUR 350,000
ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has secured loan financing of EUR 350,000 from an external...
0 Kommentare
ODI Pharma
24. Jan. 20232 Min. Lesezeit
ODI Pharma receives approval from the Office for Registration of Medicinal Products in Poland
ODI Pharma AB (“ODI” or the “Company”) announces today that the Company has received approval from the Office for Registration of...
0 Kommentare
ODI Pharma
25. Feb. 20224 Min. Lesezeit
Correction: ODI Pharma AB: Publication of half-year report 2021
Correction: ODI Pharma hereby discloses a revised half-year report for the period July – December 2021. In the previous report, the cost...
0 Kommentare
ODI Pharma
24. Feb. 20224 Min. Lesezeit
ODI Pharma AB: Publication of half-year report 2021
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2021. The report is available...
0 Kommentare
ODI Pharma
9. Juli 20212 Min. Lesezeit
ODI Pharma AB: Flagging notification
ODI Pharma AB (“ODI Pharma”) has been informed that Mr. Niclas Kappelin has acquired 20’000 shares in ODI Pharma and exceeded the...
0 Kommentare
ODI Pharma
21. Apr. 20213 Min. Lesezeit
ODI Pharma: Update on progress in “Project Poland” and “Project Skin”
In January 2021 and February 2021, ODI Pharma AB (“ODI” or the “Company”) announced the decision to expand its current business with...
0 Kommentare
ODI Pharma
22. Feb. 20212 Min. Lesezeit
ODI Pharma achieves milestone towards market entry in Poland
ODI Pharma AB (“ODI” or the “Company”) announces that its subsidiary ODI Pharma Polska Sp. z o.o. has finalized documentation and filed...
0 Kommentare
ODI Pharma
14. Jan. 20212 Min. Lesezeit
ODI Pharma proceeds with its plans and launches Project Skin
ODI Pharma AB (“ODI” or “the Company”) announces that the Board of Directors has decided to expand ODI’s current business with...
0 Kommentare
ODI Pharma
2. Nov. 20206 Min. Lesezeit
ODI PHARMA AB AND APHRIA INC. EXECUTE SUPPLY AGREEMENT
Stockholm, Sweden and Leamington, Ontario – November 2nd, 2020 – ODI Pharma AB (“ODI”, ISIN SE0013409760) today announced that, despite...
0 Kommentare
ODI Pharma
27. Aug. 20203 Min. Lesezeit
ODI Pharma AB: Publication of year-end report
ODI Pharma AB (“ODI” or “the Company”) hereby publishes its year-end report for the period July 2019 – June 2020. The report is available...
0 Kommentare
ODI Pharma
7. Apr. 20202 Min. Lesezeit
ODI Pharma AB: Status update in connection to COVID-19
ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Board of Directors does not see any impact on the Company’s mid- and...
0 Kommentare
ODI Pharma
27. Feb. 20203 Min. Lesezeit
ODI Pharma AB: Publication of half-yearly report 2019
ODI Pharma AB (“ODI” or “the Company”) hereby publishes its half-yearly report for the period October – December 2019. The report is...
0 Kommentare
ODI Pharma
20. Jan. 20202 Min. Lesezeit
First registration of ODI Pharma’s new share issue completed
Stockholm, 20.01.2020. ODI Pharma AB's ("ODI Pharma" or "Company") recently completed new share issue was significantly oversubscribed...
0 Kommentare
ODI Pharma
3. Jan. 20203 Min. Lesezeit
ODI Pharma’s new share issue prior to listing significantly oversubscribed
The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was...
0 Kommentare
bottom of page